Asahi Kasei (3407) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
14 Jul, 2026Progress toward medium-term management plan targets
On track to achieve FY2027 operating income target of ¥270 billion, driven by growth in Healthcare and AI/semiconductors sectors.
Business portfolio transformation and proactive investments support sustainable growth amid uncertainty.
Structural reforms and M&A totaling ¥1 trillion are reshaping the portfolio, with a focus on high-value-added businesses.
Record-high operating income achieved for two consecutive years, with further growth expected.
Capital allocation balances growth investment and shareholder returns, with strong operating cash flow.
Strategic business focus and sector evolution
Shift from a Material-centric structure to diversified, high-value-added businesses in Healthcare, Homes, and Electronics.
Healthcare and Electronics are prioritized for aggressive investment and are key profit drivers.
Overseas Homes and Critical Care businesses are expanding through M&A and innovation.
Material sector undergoing structural transformation, including divestitures and alliances to improve profitability.
Energy & Infrastructure pivots to ESS demand as EV market growth slows, with new capacity investments in North America.
Financial and operational performance
FY2025 operating income reached ¥231.2 billion, with ROIC at 5.9% and ROE at 8.0%.
FY2027 targets: operating income ¥270 billion, ROIC 6.0%, ROE 9.0%.
EBITDA margin projected to rise to 13.9% in FY2027.
Shareholder returns policy emphasizes progressive dividends and share repurchases, with DOE benchmark at 3%.
D/E ratio and interest-bearing debt/EBITDA maintained at healthy levels.
Latest events from Asahi Kasei
- Record earnings growth driven by Pharmaceuticals, Electronics, and Healthcare, with strong FY 2026 outlook.3407
Q4 202612 May 2026 - FY2027 operating income target of ¥270 billion is within reach, led by Healthcare and AI/semiconductors.3407
Investor presentation15 Apr 2026 - Aicuris acquisition secures a robust infectious disease pipeline, accelerating pharma growth.3407
Acquisition presentation26 Feb 2026 - Record operating income and net income growth, with an upwardly revised full-year forecast.3407
Q3 20264 Feb 2026 - Net income up 10% YoY, full-year profit guidance raised, and dividend maintained.3407
Q2 20265 Nov 2025 - Operating income rose but net income plunged on one-time and extraordinary losses; outlook and dividends improved.3407
Q1 202631 Jul 2025 - Operating and net income surged, but currency losses drove comprehensive income negative.3407
Q2 202513 Jun 2025 - Operating income jumped 128.9% YoY in Q1, with a strong outlook for FY2024.3407
Q1 202513 Jun 2025 - Record profit and acquisitions drive FY 2024; FY 2025 targets growth amid market risks.3407
Q4 20256 Jun 2025